SCHEMBL13625013

SCHEMBL13625013

CC(=O)N[C@@H](CCC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)NCCOCCOCCN=[N+]=[N-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ LMNA P02545 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ BCHE P06276 2/20 0.39
▸ ACHE P22303 2/20 0.39
▸ CACNA1C Q13936 2/20 0.39
▸ CACNA1F O60840 1/20 0.39
▸ CACNA1D Q01668 1/20 0.39
▸ CACNA1S Q13698 1/20 0.39
▸ EPOR P19235 1/20 0.39
▸ CASP1 P29466 2/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ CASP9 P55211 1/20 0.39
▸ PTGER4 P35408 3/20 0.38
▸ FOLH1 Q04609 3/20 0.38
▸ ACE P12821 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13881694 1.00 MEN1 (0.56) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890398 1.00 MEN1 (0.56) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890399 1.00 MEN1 (0.56) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890403 0.99 MEN1 (0.55) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890402 0.99 MEN1 (0.55) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890401 0.96 MEN1 (0.51) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL13890400 0.96 MEN1 (0.51) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL14012034 0.96 MEN1 (0.60) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL14012102 0.96 MEN1 (0.60) MEN1ALDH1A1HPGDKMT2ALMNA
SCHEMBL16572489 0.96 MEN1 (0.60) MEN1ALDH1A1HPGDKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides UNIVERSITY OF SOUTH FLORIDA (US) 2010-06-03 — — US disclosed
US-7618944-B2 Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-17 — — US disclosed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides IAPP, APP, TTR MEN1 271/4885ALDH1A1 4414/4885HPGD 3547/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR MEN1 227/4885ALDH1A1 4688/4885HPGD 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback